Prime Medicine stock soars amid gene editing sector momentum Investing.com -- Prime Medicine (NASDAQ:PRME) stock rose 32%, extending recent gains following Eli Lilly’s (NYSE:LLY) acquisition deal for Verve Therapeutics (NASDAQ:VERV) last month. The gene editing company has seen its shares surge approximately 160% since mid-June, building on momentum that began after a management change on May 19. The rally comes as investors reassess valuations in the gene editing sector following significant M&A activity. Several factors appear to be driving Prime Medicine’s upward trajectory, including Eli Lilly’s $1.3 billion acquisition of Verve Therapeutics, a significant price/valuation discrepancy compared to peers, substantial insider buying of 329,000 shares in the open market since mid-May, and high short interest exceeding 30% of float. The gene editing sector has seen increased acquisition interest, as evidenced by AbbVie’s (NYSE:ABBV) recent $2.1 billion purchase of Capstan Therapeutics on June 30. Jones Trading analyst Soumit Roy commented on the sector’s outlook: "VERV’s Phase 1b data was sufficient to trigger an M&A, and we believe PRME could get to the same place as they start announcing their clinical data in 2027." While Prime Medicine has yet to produce clinical data, Lilly’s acquisition of Verve suggests pharmaceutical companies are increasingly interested in gene editing technologies for treating larger market diseases, not just rare conditions with acute unmet needs.

Click Subscribe #PrimeMedicine #GeneEditing #StockMarket #Investing #Biotechnology

On the topic of the AATD-related arbitration with #BeamTherapeutics, #PrimeMedicine says AATD development candidate will include 'intentional' non-transition mutation, hence it does not infringe Beam's field which is transition-'only'.

Sounds reasonable.

#PrimeMedicine CEO said they'll complete dosing of cohort 1 in CGD trial (2-3 patients).

I believe this could be enough to get approval under new #FDA. That would be worth ~$150M currently.

#VerveTherapeutics and #PrimeMedicine should exchange clinically proven GalNAc-LNP and prime editing rights. Win-win. No need to take undue delivery safety risk here, and #Verve paid too much to #Beam for #CRISPR access.

#PrimeMedicine stopping CGD development leaves patients+investigators upset. Treatment 'should be given away for free'.

www.youtube.com/watch?v=jX_s...

Beam Therapeutics and Prime Medicine Need to Unite Prime Medicine disclosed this week that they were in binding arbitration with Beam Therapeutics regarding their development of prime editin...

Paging David Liu... #BeamTherapeutics and #PrimeMedicine Need to Unite (blog) rnaitherapeutics.blogspot.com/2025/05/beam...

#CRISPR $BEAM $PRME

If #BeamTherapeutics felt safe, they would not have to haggle with #PrimeMedicine.

AATD could well illustrate that base editing might end up being a #transitory tech, eventually supplanted by the more versatile and specific prime editing. Just buy them.

#PrimeMedicine shows that in #biotech even those illegally trading on insider info (CGD data) can lose money.

Prime Medicine stock plummets amid restructuring and leadership changes Investing.com -- Shares of Prime Medicine , Inc. (NASDAQ:PRME) tumbled 19.2% following the company’s announcement of a strategic restructuring aimed at focusing resources on large genetic liver diseases and cystic fibrosis, alongside a significant leadership transition. The Cambridge-based biotech firm disclosed plans to deprioritize its Chronic Granulomatous Disease (CGD) programs and implement cost-cutting measures, including a workforce reduction of approximately 25%. This decision comes as part of an effort to concentrate on its liver franchise and programs funded through partnerships. Prime Medicine is progressing with in vivo programs targeting Wilson’s Disease and Alpha-1 Antitrypsin Deficiency (AATD), with expectations to file an investigational new drug (IND) and/or clinical trial application (CTA) for its Wilson’s Disease program in the first half of 2026, and for its AATD program in mid-2026. Initial clinical data for both are anticipated in 2027. The company also continues its partnership with the Cystic Fibrosis Foundation and Bristol Myers (NYSE:BMY) Squibb to develop Prime Edited CAR-T products. In a leadership shake-up, Allan Reine, M.D., previously CFO, has been appointed as the new CEO, succeeding Keith Gottesdiener, M.D., effective immediately. Jeff Marrazzo, a board member, has been named Executive Chair. Dr. Reine emphasized the importance of positioning Prime Medicine to deliver on the promise of Prime Editing technology in addressing a spectrum of genetic diseases. The restructuring is expected to reduce cash needs by nearly half through 2027, with the company’s current capital expected to fund operations into the first half of 2026. This announcement was made alongside initial positive data from the Phase 1/2 clinical trial of PM359, which provided clinical proof-of-concept for Prime Editing as a transformative gene editing technology. Despite the initial positive data and the company’s commitment to its strategic programs, investors reacted negatively to the news of the restructuring and the uncertainty introduced by the executive changes. The market’s response reflects concerns over the near-term impact of the cost reductions and the potential disruption from the leadership transition. This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Click Subscribe #PrimeMedicine #StockMarket #Investing #Restructuring #LeadershipChanges

Prime Medicine Announces Strategic Restructuring to Focus on Opportunities in Large Genetic Liver Diseases, Cystic Fibrosis, and Partnered Programs Alongside CEO Leadership Transition -- Initial positive data from Phase 1/2 clinical trial of PM359 in CGD provide clinical proof-of-concept for Prime Editing as a transformative gene editing...

#PrimeMedicine in another first, #CRISPR prime editing cures a disease by repairing a (2-nt) deletion mutation.

Engraftment of ex vivo treated HSC in record time.

Cause of rareness of CGD + ex vivo, PrimeMedicine will look for somebody else to carry torch: www.globenewswire.com/news-release...

Could be one of those when stock goes up as CEO steps down. #PrimeMedicine

Also, #PrimeMedicine is in binding arbitration with #BeamTherapeutics in whether they can pursue #AATD under their agreement.

404 Page GlobeNewswire specializes in the distribution and delivery of press releases, financial disclosures and multimedia content to the media and general public.

#PrimeMedicine irony could not have been greater.

Just as #CRISPR N=1 story breaks, #Prime, with the most appropriate tech for addressing rare diseases, is pivoting to larger indications (CGD out, Wilson's+AATD '26 IND).

All to extend cash runway into H1 '26: www.globenewswire.com/news-release...

Both #Intellia and #PrimeMedicine have whopping #short interests of around 30%. Tomorrow could be monumental.

Sleep well, shorts.

#CPS1 shorts getting nervous. #PrimeMedicine after-hours showed it.

#FDA cutting red tape (see also dropping certain preclinical animal study requirements) is continuing+could dramatically shorten timelines+costs making sector investable again. #CRISPR + #oligos predestined. Monday!

Now $2 after-hours. Squeeze or still digesting #CPS1? #PrimeMedicine

#PrimeMedicine, arguably main beneficiary of #CPS1 CRISPR story yesterday up +10%+ today. Just saying.

#FDA Peter Marks sees it the same way. This is a big deal, doubt 'new FDA' will backtrack on #platform approach.

Beneficiaries, #PrimeMedicine, to some degree #Beam (when certain single nucleotide mutations involved).

#BeamTherapeutics got to wonder why #PrimeMedicine is going after AATD as well.

If Beam's base editing-LNPs good enough in terms of efficacy, is Prime spotting an opening in safety, e.g. bystander or esp Genevant-derived LNPs?

$PRME #PrimeMedicine I also did not like the uncertainty RE timing of first clinical data. Clearly, focus/value is on AATD and Wilson's disease (CTA/INDs next year).

They will survive though. They have the IP and know-how.

Also: #PrimeMedicine first ever human data. The stuff that will be widely reported.

#PrimeMedicine it is a great irony that as other #CRISPR companies shift their focus towards more common diseases, the biotech with the 'best' (most versatile, safest) tech has maneuvered itself into the ultra-/rare disease corner.

At what point will #Chinese biotechs buy up Western #biotechs with critical tech and IP, incl #PrimeMedicine and #ProQR?